Advs. Simon Weintraub and Daniel Green represented China International Capital Corporation Hong Kong Securities Limited and Jefferies Hong Kong Limited, the joint sponsors (underwriters) in connection with the initial public offering of Sisram Medical – the first Israeli company to list on the Hong Kong Stock Exchange. The global offering of Sisram’s shares raised approximately US $112 million. Sisram Medical, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., had previously acquired Alma Lasers Ltd., an international company headquartered in Israel and a global leader in the field of energy-based systems for the aesthetic and surgical markets.
In addition, our firm was involved in the process of having the State of Israel recognized as an “accepted jurisdiction” by the HKSE which will hopefully lead to future opportunities for Israeli companies seeking to list their shares on the Hong Kong Stock Exchange.
Daniel Green and Simon Weintraub participated in an article in the Medical Device Daily Magazine.
Advs. Daniel Green and Eli Greenbaum represented Oramed Pharmaceuticals, an Israeli clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, in a licensing transaction with Hefei Tianhui Incubator of Technologies Co., Ltd., of China. The agreement is worth $38 million, with future royalties, and gives HTIT exclusive rights to market Oramed’s oral insulin capsule, in China, Hong Kong and Macau. This deal is alongside a $12 million equity investment in the company.